Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 8/20 | 0.50 |
| ▸ | PLK1 | P53350 | 4/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.44 |
| ▸ | BID | P55957 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11710027 | 0.79 | FOLH1 (0.61) | SLC16A3FOLH1SMN1; SMN2BIDBCL2L1 | |
| SCHEMBL3554093 | 0.77 | HDAC3 (0.56) | SLC16A3SMN1; SMN2HDAC1 | |
| SCHEMBL9345842 | 0.77 | FOLH1 (0.68) | SLC16A3FOLH1BIDBCL2L1MCL1 | |
| SCHEMBL10641089 | 0.76 | TSHR (0.68) | SLC16A3PLK1FOLH1PLK3 | |
| SCHEMBL20162476 | 0.75 | FOLH1 (0.61) | SLC16A3FOLH1SMN1; SMN2BIDBCL2L1 | |
| SCHEMBL729909 | 0.75 | FOLH1 (0.70) | SLC16A3FOLH1KDM4ESMN1; SMN2BID | |
| SCHEMBL370919 | 0.75 | SLC16A3 (0.58) | SLC16A3PLK1FOLH1BIDBCL2L1 | |
| SCHEMBL9644336 | 0.75 | SLC16A3 (0.62) | SLC16A3PLK1FOLH1PLK3BID | |
| SCHEMBL10641755 | 0.75 | CYP4A11 (0.60) | SLC16A3PLK1LMNAPLK3 | |
| SCHEMBL6486936 | 0.74 | MEN1 (0.48) | SLC16A3PLK1KDM4EPLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885PLK1 4876/4885FOLH1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.